eccogene glp-1 Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule Receptor Agonist ECC5004 for Cardiometabolic Diseases Eccogene files for Hong Kong

Expected Weight-Loss Results Weight loss with GLP-1 medications is steady and progressive rather than sudden

If you have been diagnosed with diabetes, speak with your healthcare provider about switching to Mounjaro which contains the same active ingredient as Zepbound (tirzepatide) and is approved for type 2 diabetes

Typically, the eligibility criteria for GLP-1 medication are: a body mass index (BMI) score of 30 or over a BMI of 27 or over and a weight-related health condition The weight-related health conditions can include those such as diabetes, high cholesterol, or high blood pressure

PMID: 46 DruckerDJ

Or, have an apple with a small portion of natural peanut butter

Ozempic, Wegovy, Mounjaro, Zepbound 1 in 5 adults have now tried one